Kevin Feeley Sells 1,285 Shares of GeneDx (NASDAQ:WGS) Stock

by · The Markets Daily

GeneDx Holdings Corp. (NASDAQ:WGS – Get Free Report) CFO Kevin Feeley sold 1,285 shares of the firm’s stock in a transaction dated Wednesday, September 9th. The stock was sold at an average price of $84.22, for a total value of $108,222.70. Following the completion of the sale, the chief financial officer directly owned 41,476 shares in the company, valued at $3,493,108.72. The trade was a 3.01% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Kevin Feeley also recently made the following trade(s):

  • On Tuesday, June 16th, Kevin Feeley sold 3,729 shares of GeneDx stock. The shares were sold at an average price of $60.77, for a total value of $226,611.33.

GeneDx Trading Up 1.5%

NASDAQ WGS opened at $85.26 on Friday. GeneDx Holdings Corp. has a fifty-two week low of $32.21 and a fifty-two week high of $170.87. The company has a debt-to-equity ratio of 0.40, a quick ratio of 3.06 and a current ratio of 3.30. The stock has a 50 day simple moving average of $74.67 and a two-hundred day simple moving average of $66.78. The stock has a market cap of $2.54 billion, a P/E ratio of -23.42 and a beta of 1.99.

GeneDx (NASDAQ:WGS – Get Free Report) last issued its quarterly earnings data on Monday, August 3rd. The company reported $0.01 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.20. The firm had revenue of $114.44 million for the quarter, compared to analyst estimates of $111.01 million. GeneDx had a positive return on equity of 4.12% and a negative net margin of 23.41%.During the same period last year, the company earned $0.36 EPS. On average, analysts forecast that GeneDx Holdings Corp. will post -0.41 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several brokerages have commented on WGS. Canaccord Genuity Group upped their price objective on shares of GeneDx from $75.00 to $90.00 and gave the stock a “buy” rating in a report on Tuesday, August 4th. Wall Street Zen upgraded shares of GeneDx from a “sell” rating to a “hold” rating in a research report on Saturday, August 8th. TD Cowen reiterated a “buy” rating on shares of GeneDx in a research report on Wednesday, July 15th. Guggenheim reissued a “buy” rating and issued a $74.00 price target (up from $70.00) on shares of GeneDx in a research note on Monday, June 29th. Finally, BTIG Research restated a “buy” rating and issued a $90.00 price objective on shares of GeneDx in a report on Tuesday, August 4th. One research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $89.57.

Read Our Latest Stock Analysis on WGS

Institutional Trading of GeneDx

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Bank of America Corp DE boosted its stake in GeneDx by 77.5% in the 1st quarter. Bank of America Corp DE now owns 234,606 shares of the company’s stock worth $15,066,000 after purchasing an additional 102,456 shares in the last quarter. Sumitomo Mitsui Trust Group Inc. increased its stake in GeneDx by 65.9% during the 1st quarter. Sumitomo Mitsui Trust Group Inc. now owns 633,457 shares of the company’s stock valued at $40,681,000 after purchasing an additional 251,732 shares in the last quarter. Goldman Sachs Group Inc. raised its holdings in GeneDx by 4.5% in the fourth quarter. Goldman Sachs Group Inc. now owns 1,220,502 shares of the company’s stock worth $158,738,000 after buying an additional 52,322 shares during the last quarter. Lazard Asset Management LLC purchased a new position in GeneDx in the first quarter worth about $2,177,000. Finally, Bank of New York Mellon Corp lifted its stake in shares of GeneDx by 38.6% in the first quarter. Bank of New York Mellon Corp now owns 315,508 shares of the company’s stock worth $20,262,000 after buying an additional 87,922 shares in the last quarter. 61.72% of the stock is owned by hedge funds and other institutional investors.

GeneDx Company Profile

(Get Free Report)

GeneDx Holdings Corp., doing business as GeneDx, is a healthcare company focused on genetic testing and genomic diagnostics. The company provides testing designed to help healthcare professionals diagnose rare and inherited conditions, guide clinical management, and support research into genetic disease.

Its offerings include whole exome and whole genome sequencing, targeted genetic tests, chromosomal microarray analysis, and other tests used to identify disease-causing genetic variants.

See Also